Endocrine Oncology
@EndoOncology
Followers
1K
Following
198
Media
352
Statuses
460
An #OpenAccess, peer-reviewed journal from @Soc_Endo & @bioscientifica. Publishing research & reviews on hormone-related cancer & cancers of #endocrine organs.
Joined November 2020
📢 Endocrine Oncology is pausing activity on X. To stay up to date with journal news and research, follow us on: 🌐LinkedIn: https://t.co/pA3eaPalQU 🦋Bluesky: https://t.co/y4JXFtEepq Thanks for staying connected and being part of our community!
0
0
0
Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19. The NETRF Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other. Register now: https://t.co/s9vxiqhi30
#NETresearch
0
1
1
🆕A retrospective case series by Eleni Armeni et al. from @RoyalFreeNHS explores the diagnostic & therapeutic complexities of glucagonomas, offering a valuable reference point for clinicians & researchers navigating the field. 🔗Read the article: https://t.co/c5K7EppA31
0
0
3
🌐 Endocrine Oncology has joined LinkedIn! We're excited to connect with the global endocrine oncology community in a new space. Follow us for the latest journal articles, special collections and key updates. 🌐 https://t.co/pA3eaP9O1m
0
0
1
➡️ Don’t forget to submit your #ENSAT2025 study to our @bioscientifica @EndoOncology special collection dedicated to #adrenal tumours! #ACC #PPGL #APA #NAPACA
🗞️Excited to announce a new special collection in collaboration with @bioscientifica @EndoOncology. Editors invite submissions of original research/reviews/case reports from speakers & delegates attending the ENS@T Annual Meeting (4-5/09/2025 Belgrade). https://t.co/rK6C9cBzOB
0
2
6
Research by Kim Dijke et al. highlights the distinct differences in disease course of appendiceal NETs & appendiceal goblet cell adenocarcinomas, supporting the exclusion of aGCAs from the group of NENs in the 5th #WHO classification. Explore more: https://t.co/9pwVTenS0H
0
0
0
🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours! We welcome basic, translational & clinical studies that advance understanding & showcase innovations. 📩Submit your proposal to: erc@bioscientifica.com 🌐More info: https://t.co/0zbvtYYt2H
0
1
2
🆕Tumour Heterogeneity in Neuroendocrine Neoplasms #NENs We are inviting submissions of research on the biological & clinical characterisation of NEN heterogeneity, highlighting the impact on prognosis & treatment outcomes. 🌐For more info visit https://t.co/tjhms1grVN
0
0
2
🧬A new systematic review and meta-analysis by M P Aguiar et al. links estrogen-related gene polymorphisms to ovarian cancer occurrence/susceptibility, uncovering variants in CYP17A1, COMT and GSTP1 that may be associated with risk. 🔗Read the review: https://t.co/gKLnCe8fLf
0
0
2
🌱Endocrine-Related Cancer is officially on LinkedIn! Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal: 🌐 https://t.co/k66BVrDACs
0
1
3
🔬Latest research by Lara Toffoli et al. (@uniud) investigates the impact of FAK inhibition on GI neuroendocrine tumors (GI-NETs) demonstrating its pivotal role in pathogenesis of GI-NETs & supporting its therapeutic targeting. 👉Read the full article: https://t.co/83FReaUMcx
0
0
1
Huge thanks to all who supported us 🙏 📄 Open Access: https://t.co/FrCwq8eGfm
#CancerResearch #FAK #NeuroendocrineTumors #TeamScience
eo.bioscientifica.com
Background Gastrointestinal neuroendocrine tumors (GI-NETs) are rare neoplasms with limited therapeutic options and increasing clinical incidence. Focal adhesion kinase (FAK) has been implicated in...
0
1
2
💗 Proud of my young research group 💗 Despite limited resources & challenges, we’ve published in #EndocrineOncology Our study on FAK inhibition in GI-NETs shows: ⚡ Dual kinase + scaffold targeting ⚡ ↓ tumor growth & invasion ⚡ Epigenetic effects
1
2
2
Your research can help advance hormone-dependent cancer treatment and improve patient care. Abstract submissions close Monday 15 Sept: https://t.co/RGqhX8Ok4L
0
1
2
Sponsored by @CureNETs, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research. Learn more: https://t.co/EOC9DMUdcv
#neuroendocrinecancer #earlycareerresearcher
0
0
1
@EndoOncology's special collection celebrates women in Neuroendocrine Tumour (NET) research.Original research, reviews are welcome!🔗 https://t.co/ECnSjDR5HP… Submit to: eo@bioscientifica.com @GCarboneroLab @simonag56739514 @MGMcNamara @helops79 @FRANCES88189587 @DrAngelaLamarca
1
6
9
📈Incidence & prevalence of neuroendocrine neoplasms continues to rise globally. A new review by Jessica Mangion et al. explores global epidemiological data, reviewing trends & differences in incidence rates to improve our understanding of this rise. 🔗 https://t.co/8MG01cvNLo
0
0
2
🔍Somatostatin analogues (SSA) can unmask insulinoma in presumed non-functional GEP-NETs. A new case report by Isuru Gamage et al. presents two cases where SSA unmasked hypoglycaemia due to insulinoma. 📖 Check out the full report: https://t.co/Pk8FPuLLP7
0
1
3
Could a new class of drugs be an effective treatment option for #ProstateCancer? A brilliant team including several @ProstateUK-funded researchers @EssexLifeSci and @imperialcollege share exciting new findings in @EndoOncology. Grab a ☕ and read: https://t.co/tN9P4tz8ZK
0
2
9
🧠A new systematic review and meta-analysis by Tatiana Tselovalnikova et al. highlights why long-term monitoring is crucial after cranial irradiation as growth hormone deficiency can develop years post-treatment. 👉Read the full article: https://t.co/gfq9N0J9sg
0
0
1